NCT04796194 - Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions

Advanced Melanoma

Interventions

COMBINATION_PRODUCT

LTX-315 in combination with pembrolizumab

"Phase A Pembrolizumab will be given as 200 mg IV infusion over 30 minutes on Days 1 and 22.~Phase B Pembrolizumab will be given as 400 mg IV infusion over 30 minutes every 6 weeks starting at Day 43 (3 weeks after the last dose of pembrolizumab in Phase A) until discontinuation from the study or for a maximum of 24 months' total therapy, whichever comes first."

Trial Locations (10)

10029

Icahn School of Medicine at Mount Sinai, New York

15232

University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center, Pittsburgh

28204

Levine Cancer Institute - Atrium Health, Charlotte

77030

MD Anderson Cancer Centre, Houston

Unknown

Centre Hospitalier Regional Universitaire De Lille, Lille

Gustave Roussy Cancer Campus, Paris

Hospital Lyon Sud, Pierre-Bénite

Akershus University Hospital, Lørenskog

Oslo University Hospital--Radiumhospitalet, Oslo

Clínica Universidad de Navarra, Pamplona